219 related articles for article (PubMed ID: 16695984)
1. The study of minimal residual disease in acute lymphoblastic leukaemia.
Knechtli CJ; Goulden NJ; Langlands K; Potter MN
Clin Mol Pathol; 1995 Apr; 48(2):M65-73. PubMed ID: 16695984
[No Abstract] [Full Text] [Related]
2. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin gene rearrangement in detection of minimal residual disease in acute lymphoblastic leukaemia.
Nayyar A; Ahmed S
J Ayub Med Coll Abbottabad; 2013; 25(1-2):159-61. PubMed ID: 25098084
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia.
Eckert C; Biondi A; Seeger K; Cazzaniga G; Hartmann R; Beyermann B; Pogodda M; Proba J; Henze G
Lancet; 2001 Oct; 358(9289):1239-41. PubMed ID: 11675066
[TBL] [Abstract][Full Text] [Related]
5. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
Tucunduva L; Ruggeri A; Sanz G; Furst S; Cornelissen J; Linkesch W; Mannone L; Ribera JM; Veelken H; Yakoub-Agha I; González Valentín ME; Schots R; Arcese W; Montesinos P; Labopin M; Gluckman E; Mohty M; Rocha V
Br J Haematol; 2014 Sep; 166(5):749-57. PubMed ID: 24961645
[TBL] [Abstract][Full Text] [Related]
6. The detection of minimal residual disease in acute lymphoblastic leukaemia.
Potter MN
Blood Rev; 1992 Jun; 6(2):68-82. PubMed ID: 1633509
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction.
Kwan E; Norris MD; Zhu L; Ferrara D; Marshall GM; Haber M
Br J Haematol; 2000 May; 109(2):430-4. PubMed ID: 10848837
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
Sekiya Y; Xu Y; Muramatsu H; Okuno Y; Narita A; Suzuki K; Wang X; Kawashima N; Sakaguchi H; Yoshida N; Hama A; Takahashi Y; Kato K; Kojima S
Br J Haematol; 2017 Jan; 176(2):248-257. PubMed ID: 27861730
[TBL] [Abstract][Full Text] [Related]
10. Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia.
Radich JP
Best Pract Res Clin Haematol; 2002 Mar; 15(1):91-103. PubMed ID: 11987918
[TBL] [Abstract][Full Text] [Related]
11. Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
Ifversen M; Turkiewicz D; Marquart HV; Winiarski J; Buechner J; Mellgren K; Arvidson J; Rascon J; Körgvee LT; Madsen HO; Abrahamsson J; Lund B; Jonsson OG; Heilmann C; Heyman M; Schmiegelow K; Vettenranta K
Br J Haematol; 2019 Mar; 184(6):982-993. PubMed ID: 30680711
[TBL] [Abstract][Full Text] [Related]
12. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
[TBL] [Abstract][Full Text] [Related]
13. Comparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemia.
Paula FD; Elói-Santos SM; Xavier SG; Ganazza MA; Jotta PY; Yunes JA; Viana MB; Assumpção JG
Rev Bras Hematol Hemoter; 2015; 37(6):373-80. PubMed ID: 26670399
[TBL] [Abstract][Full Text] [Related]
14. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
[TBL] [Abstract][Full Text] [Related]
15. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
16. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
17. Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
Giusti GNN; Jotta PY; Lopes CO; Ganazza MA; de Azevedo AC; Brandalise SR; Meidanis J; Yunes JA
Br J Haematol; 2020 May; 189(4):e150-e154. PubMed ID: 32187384
[No Abstract] [Full Text] [Related]
18. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia.
Brisco MJ; Sykes PJ; Hughes E; Dolman G; Neoh SH; Peng LM; Toogood I; Morley AA
Br J Haematol; 1997 Nov; 99(2):314-9. PubMed ID: 9375747
[TBL] [Abstract][Full Text] [Related]
19. "Mouse-MRD" in central nervous system acute lymphoblastic leukaemia: assessing bone marrow minimal residual disease using a xenograft model - from bedside to the bench and back again.
Alten J; Claviez A; Vieth S; Cario G; Schewe DM
Br J Haematol; 2018 Nov; 183(4):686-688. PubMed ID: 29193025
[No Abstract] [Full Text] [Related]
20. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.
Coustan-Smith E; Behm FG; Sanchez J; Boyett JM; Hancock ML; Raimondi SC; Rubnitz JE; Rivera GK; Sandlund JT; Pui CH; Campana D
Lancet; 1998 Feb; 351(9102):550-4. PubMed ID: 9492773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
